TY - JOUR AU - Sung S AU - Kobayashi TT AB -
Leprosy is a chronic granulomatous infection caused by the organism Mycobacterium leprae that primarily affects the skin and peripheral nerves. Leprosy has several distinct clinical presentations ranging from moderate to severe, with the extent of disease generally depending on the host's immune response to the infection. Treatment typically involves antimicrobials (eg, clofazimine, dapsone, rifampin). Once treatment is started, an important aspect of patient care is the recognition of possible reversal reactions. We report the case of a 44-year-old man who repeatedly developed physical findings consistent with a type 1 (reversal) reaction after undergoing multiple treatments for leprosy. A discussion of leprosy along with its clinical manifestations, treatment methods, and management of reversal reactions also is provided.
BT - Cutis C1 -http://www.ncbi.nlm.nih.gov/pubmed/25942024?dopt=Abstract
IS - 4 J2 - Cutis LA - eng N2 -Leprosy is a chronic granulomatous infection caused by the organism Mycobacterium leprae that primarily affects the skin and peripheral nerves. Leprosy has several distinct clinical presentations ranging from moderate to severe, with the extent of disease generally depending on the host's immune response to the infection. Treatment typically involves antimicrobials (eg, clofazimine, dapsone, rifampin). Once treatment is started, an important aspect of patient care is the recognition of possible reversal reactions. We report the case of a 44-year-old man who repeatedly developed physical findings consistent with a type 1 (reversal) reaction after undergoing multiple treatments for leprosy. A discussion of leprosy along with its clinical manifestations, treatment methods, and management of reversal reactions also is provided.
PY - 2015 SP - 222 EP - 6 T2 - Cutis TI - Diagnosis and treatment of leprosy type 1 (reversal) reaction. UR - https://www.mdedge.com/cutis/article/98675/infectious-diseases/diagnosis-and-treatment-leprosy-type-1-reversal-reaction/page/0/1 VL - 95 SN - 2326-6929 ER -